Article
IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F.
Leukemia - 1 Mar 2012
Tefferi A, Jimma T, Sulai N H, Lasho T L, Finke C M, Knudson R A, McClure R F, Pardanani A
Abstract excerpt
Isocitrate dehydrogenase (IDH) mutations are frequent in blast-phase myeloproliferative neoplasms and might therefore contribute to leukemic transformation. We examined this possibility in 301 consecutive patients with chronic-phase primary myelofibrosis (PMF). The mutant IDH was detected in 12 patients (4%): 7 IDH2 (5 R140Q, 1 R140W and 1 R172G) and 5 IDH1 (3 R132S and 2 R132C). In all, 6 (50%) of the 12...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.